|
16.03.2016 08:30:01
|
DGAP-News: MOLOGEN AG
DGAP-News: MOLOGEN AG appoints Walter Miller as new CFO
16.03.2016 / 08:30 The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press release N 5/ 2016 of 03/16/2016
MOLOGEN AG appoints Walter Miller as new CFO
Berlin, 16 March 2016 - The Supervisory Board of biotechnology company MOLOGEN AG (ISIN DE0006637200, Prime Standard of the Frankfurt Stock Exchange: MGN) today appointed Walter Miller as member of the Executive Board and new Chief Financial Officer (CFO) of MOLOGEN AG with effect from 1 April 2016.
Upon taking office, Walter Miller will have responsibility within the company for Finance and Administration as well as the Risk Management, Compliance and Corporate Governance departments.
Oliver Krautscheid, Chairman of the Supervisory Board at MOLOGEN AG, explained: "We are delighted to welcome Mr. Miller on board. He is an excellent Chief Financial Officer with experience and expertise in the biotech and pharma industry. In addition to his skills acquired in commercial roles, he also has extensive experience in licensing activities and capital market related topics. As part of previous roles, he has also overseen various financing transactions. His knowledge and experience will make a decisive contribution to advancing MOLOGEN's development from a research-based biotech company to a biopharmaceutical product company."
"I see this as an exciting new challenge. Taking forward a company like MOLOGEN, with its promising drug candidates in development, requires a solid organizational structure with a market and product focus. I particularly look forward to working with the highly committed and experienced MOLOGEN team, without whom the successful implementation of the corporate strategy will not be possible", said Walter Miller.
With more than 15 years of experience in the biotechnology and pharmaceutical sector, Walter Miller has worked at both start-ups and listed companies in Germany and abroad. He was most recently CFO on the management team of Nuvisan GmbH, an international contract research organization (CRO) and laboratory services provider. He was responsible for Finance, Legal, Purchasing and IT at the company from June 2013. Prior to joining Nuvisan, he held various managerial posts at the listed Santhera Pharmaceuticals Group. As Vice President Finance & Commercial Operations, initially in Germany as well as subsequently in Switzerland, he was also a member of the Group's management team. Walter Miller started his professional career at ISRA VISION PARSYTEC in Aachen, Germany.
MOLOGEN AG With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.
The cancer immunotherapy lefitolimod (MGN1703) is the company's lead product and best-in-class TLR9 agonist. Treatment with lefitolimod (MGN1703) triggers a broad and strong activation of the immune system. Due to this mechanism of action, lefitolimod (MGN1703) has the potential to be applied to various indications. Lefitolimod (MGN1703) is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore, it is also being investigated in a phase I study in HIV and a phase I combination study with the checkpoint inhibitor Yervoy(R) (ipilimumab) is expected to start within the first half 2016.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need.
www.mologen.com
Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)
MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com
Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.
---------------------------------------------------------------------------
16.03.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News Service ---------------------------------------------------------------------------
445635 16.03.2016
DGAP-News: MOLOGEN AG / Key word(s): Change of Personnel MOLOGEN AG appoints Walter Miller as new CFO
16.03.2016 / 08:30 The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press release N 5/ 2016 of 03/16/2016
MOLOGEN AG appoints Walter Miller as new CFO
Berlin, 16 March 2016 - The Supervisory Board of biotechnology company MOLOGEN AG (ISIN DE0006637200, Prime Standard of the Frankfurt Stock Exchange: MGN) today appointed Walter Miller as member of the Executive Board and new Chief Financial Officer (CFO) of MOLOGEN AG with effect from 1 April 2016.
Upon taking office, Walter Miller will have responsibility within the company for Finance and Administration as well as the Risk Management, Compliance and Corporate Governance departments.
Oliver Krautscheid, Chairman of the Supervisory Board at MOLOGEN AG, explained: "We are delighted to welcome Mr. Miller on board. He is an excellent Chief Financial Officer with experience and expertise in the biotech and pharma industry. In addition to his skills acquired in commercial roles, he also has extensive experience in licensing activities and capital market related topics. As part of previous roles, he has also overseen various financing transactions. His knowledge and experience will make a decisive contribution to advancing MOLOGEN's development from a research-based biotech company to a biopharmaceutical product company."
"I see this as an exciting new challenge. Taking forward a company like MOLOGEN, with its promising drug candidates in development, requires a solid organizational structure with a market and product focus. I particularly look forward to working with the highly committed and experienced MOLOGEN team, without whom the successful implementation of the corporate strategy will not be possible", said Walter Miller.
With more than 15 years of experience in the biotechnology and pharmaceutical sector, Walter Miller has worked at both start-ups and listed companies in Germany and abroad. He was most recently CFO on the management team of Nuvisan GmbH, an international contract research organization (CRO) and laboratory services provider. He was responsible for Finance, Legal, Purchasing and IT at the company from June 2013. Prior to joining Nuvisan, he held various managerial posts at the listed Santhera Pharmaceuticals Group. As Vice President Finance & Commercial Operations, initially in Germany as well as subsequently in Switzerland, he was also a member of the Group's management team. Walter Miller started his professional career at ISRA VISION PARSYTEC in Aachen, Germany.
MOLOGEN AG With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.
The cancer immunotherapy lefitolimod (MGN1703) is the company's lead product and best-in-class TLR9 agonist. Treatment with lefitolimod (MGN1703) triggers a broad and strong activation of the immune system. Due to this mechanism of action, lefitolimod (MGN1703) has the potential to be applied to various indications. Lefitolimod (MGN1703) is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore, it is also being investigated in a phase I study in HIV and a phase I combination study with the checkpoint inhibitor Yervoy(R) (ipilimumab) is expected to start within the first half 2016.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need.
www.mologen.com
Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)
MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com
Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.
---------------------------------------------------------------------------
16.03.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News Service ---------------------------------------------------------------------------
445635 16.03.2016
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu MOLOGEN AGmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu MOLOGEN AGmehr Analysen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.